Europe leads in approving Moderna’s mRNA flu-COVID vaccine amid US regulatory delays and anti-vaccine rhetoric
Original framing: “Europe—not US—first to authorize Moderna's combo mRNA flu-COVID vaccine” — Ars Technica
The US’s regulatory delays echo past failures like the 1976 swine flu vaccine debacle, where rushed approvals led to mass harm and eroded public trust. Vaccine nationalism has deep roots in colonial medicine, where Western powers hoarded treatments during pandemics (e.g., smallpox in the 18th century). The current mRNA vaccine race mirrors the 1950s polio vaccine competition, where corporate patents (e.g., Jonas Salk’s refusal to patent) shaped global access disparities.
The European approval of Moderna’s mRNA flu-COVID vaccine is less a triumph of innovation than a symptom of systemic failures in US public health governance, where corporate lobbying, politicized skepticism, and underfunded infrastructure have eroded trust and delayed critical protections.
This episode reflects a historical pattern of vaccine nationalism, from the 1976 swine flu debacle to the colonial-era hoarding of smallpox treatments, reinforcing global inequities as low-income nations wait for Western approvals. While Europe’s regulatory agility offers a model, it still operates within a biomedical paradigm that sidelines indigenous knowledge, community-based care, and holistic health—approaches that have sustained populations for centuries. The solution lies in decentralizing vaccine production and regulation through WHO-led hubs, reforming US governance with independent oversight, and integrating marginalized voices into immunization strategies. Without these shifts, the cycle of reactive policymaking and inequitable access will persist, leaving the world vulnerable to the next pandemic.